Recent Investment Analysts’ Ratings Changes for Bioventus (BVS)

A number of research firms have changed their ratings and price targets for Bioventus (NASDAQ: BVS):

• 8/17/2026 – Bioventus had its price target raised by Canaccord Genuity Group Inc. from $15.00 to $19.00. They now have a “buy” rating on the stock.
• 8/17/2026 – Bioventus had its “overweight” rating reaffirmed by Cantor Fitzgerald. They now have a $15.00 price target on the stock.
• 8/6/2026 – Bioventus was upgraded by Weiss Ratings from “hold (c)” to “hold (c+)”.
• 8/6/2026 – Bioventus had its “buy” rating reaffirmed by Craig Hallum. They now have a $18.00 price target on the stock.
• 8/6/2026 – Bioventus was given a new $18.00 price target by Barrington Research.
• 6/30/2026 – Bioventus had its “outperform” rating reaffirmed by Barrington Research. They now have a $14.00 price target on the stock.

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.